Neurodegenerative Diseases News and Research

RSS

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

UC Irvine study: Small amount of brain bleeding is common among older individuals

Neurologist Dr. Mark Fisher and neuropathologist Dr. Ronald Kim found that cerebral microbleeds are highly prevalent in the aging brain - and not primarily products of stroke-related injury, hypertension or neurodegenerative diseases such as Alzheimer's, as had been thought.

9 Nov 2010

Eli Lilly to acquire Avid Radiopharmaceuticals

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that partner company Avid Radiopharmaceuticals, Inc. has signed a definitive merger agreement to be acquired by Eli Lilly and Company.

8 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

New findings provide new clues on pathogenetic mechanisms of Alzheimer's disease

Pathological protein deposits linked to Alzheimer's disease and cerebral amyloid angiopathy can be triggered not only by the administration of pathogenic misfolded protein fragments directly into the brain but also by peripheral administration outside the brain.

22 Oct 2010

Researchers discover link between hereditary and sporadic ALS

For the first time, researchers have discovered a disease mechanism that links hereditary amyotrophic lateral sclerosis to the more common "sporadic" form of ALS and points to a possible therapeutic target.

21 Oct 2010

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Finding a drug that can cross the blood-brain barrier is the bane of drug development for Alzheimer's disease and other neurological disorders of the brain. A new Penn study, published this week in the Journal of Neuroscience, has found and tested in an animal model of Alzheimer's disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.

19 Oct 2010

UCSF professor receives National Medal of Science

UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.

18 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

Scientists find pericytes regulate blood-brain barrier

14 Oct 2010

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.

14 Oct 2010

Plant compound luteolin reduces age-associated inflammation in brain leading to better cognitive health

A diet rich in the plant compound luteolin reduces age-related inflammation in the brain and related memory deficits by directly inhibiting the release of inflammatory molecules in the brain, researchers report.

14 Oct 2010

Synosia announces $30M Series C financing

Synosia Therapeutics, a privately held biotherapeutics company focused on neurology and psychiatry, today announced that it has raised $30M in a Series C financing round.

12 Oct 2010

Health-TIES consortium aims to accelerate innovation in healthcare

On Thursday 7 October, Europe's top regions in healthcare technology will launch the Health-TIES consortium that aims to accelerate innovation in healthcare. The consortium is backed by a three-year grant from the European Commission and is set up to strengthen the research potential of European regions through research-driven clusters of universities, research centres, enterprises and regional authorities.

8 Oct 2010

Microglial inflammation promotes MAPT pathologies

Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research, published by Cell Press in the October 7th issue of the journal Neuron, provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.

7 Oct 2010

Saneron receives grant to develop safety guidelines for transplanting HUBC cells in Alzheimer's disease

The National Institutes of Health has awarded a three-year, $2.6-million grant to the University of South Florida and Tampa-based biotechnology company Saneron-CCEL Therapeutics, Inc., to establish dosing and safety guidelines for transplanting human umbilical cord blood cells (HUBC) into animal models of Alzheimer's disease.

6 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Scientists discover c-Abl protein role in Parkinson's disease progression

Johns Hopkins scientists have discovered that the over-activation of a single protein may shut down the brain-protecting effects of a molecule and facilitate the most common form of Parkinson's disease.

4 Oct 2010

Neurodegenerative Diseases News and Research

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

DHA protects brain tissue and promotes recovery in acute ischemic stroke

UC Irvine study: Small amount of brain bleeding is common among older individuals

Eli Lilly to acquire Avid Radiopharmaceuticals

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

New findings provide new clues on pathogenetic mechanisms of Alzheimer's disease

Researchers discover link between hereditary and sporadic ALS

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

UCSF professor receives National Medal of Science

Pericytes regulate blood-brain barrier

Scientists find pericytes regulate blood-brain barrier

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Plant compound luteolin reduces age-associated inflammation in brain leading to better cognitive health

Synosia announces $30M Series C financing

Health-TIES consortium aims to accelerate innovation in healthcare

Microglial inflammation promotes MAPT pathologies

Saneron receives grant to develop safety guidelines for transplanting HUBC cells in Alzheimer's disease

Neuraltus achieves last patient out for NP001, NP002 studies

NIH to award $64M under Transformative Research Projects program

Scientists discover c-Abl protein role in Parkinson's disease progression

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News